Abstract - -- Introduction: Psychosis spectrum disorders are characterized by both positive and negative symptoms, but whereas there is good effect of treatment on positive symptoms, there is still a scarcity of effective interventions aimed at reducing negative symptoms. Rumination has been proposed as an important and fundamental factor in the development and maintenance of symptoms across psychiatric diagnoses, and there is a need to develop effective interventions targeting rumination behaviors and negative symptoms in patients with psychotic disorders. The aim of the current study is to investigate the feasibility and acceptability of group rumination-focused cognitive behavioral therapy (RFCBT) in the treatment of young people with psychosis spectrum disorders as well as investigating potential indications of treatment efficacy. Methods and analysis: The study is a mixed-method clinical randomized controlled pilot trial with a target sample of 60 patients, who are randomized to either receive 13 weeks of group CFCBT or 13 weeks of treatment as usual (TAU). All patients are examined at the start of the project and at the 13-week follow-up. The researcher will compare changes in outcomes from baseline to posttreatment between group CFCBT and TAU. In addition, qualitative analyzes are carried out to explore feasibility and acceptability and to uncover the patients' experience of receiving the intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
Psychotherapy
opus treatment
Mental Health Centre Copenhagen
Copenhagen, Denmark
RECRUITINGthe Brief Negative Symptoms Scale (BNSS)
Assessment of negative symptoms on a scale from 0-78
Time frame: up to 20 weeks
Perseverative Thinking Questionnaire (PTQ)
Measuring frequency of rumination. Resulting in a total score of 0-60.
Time frame: up to 20 weeks
Ruminative Response Scale (RRS)
Measuring levels of rumination in relation to depression. Resulting in a total score of 22-88.
Time frame: up to 20 weeks
Social Functioning Scale (SFS)
Measuring level of functioning on a scale from of 0-228
Time frame: up to 20 weeks
Scale for the assessment of positive symptoms (SAPS)
Measuring presence of positive symptoms on a scale from 0-170
Time frame: up to 20 weeks
Calgary depression scale (CDS)
Measuring depressive symptoms on a scale from 0-27
Time frame: up to 20 weeks
Behavior Rating Inventory of Executive Function (BRIEF)
Measuring executive functioning on a scale from 75-225
Time frame: up to 20 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.